Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Jayakrishna Ambati
University of Virginia, Department: Ophthalmology
Should you be removed from our database? Contact us at [email protected]. Read more below.
iVeena Pharmaceuticals, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Ambati has recently arrived at UVA. While on the faculty at U of Kentucky he co-founded a company, iVeena Pharaceuticals, which licensed IP from U Kentucky related to inflammasome treatments for macular degeneration. Inflammasome biology in macular degeneration is the focus of this NIH R01 grant. The UVA Conflict of Interest Committee determined that this SFI in iVeena Pharaceuticals could effect the design, conduct or reporting of this research.
Inflammasome Activation in Geographic Atrophy
There is no FDA-approved treatment for the one million Americans with geographic atrophy (GA) or for the millions more who are at risk of developing GA. We recently discovered an enzymatic deficiency that leads to accumulation of toxic RNA molecules and immune activation in the eyes of patients with GA. By understanding how these newly discovered pathways cause GA and testing therapies that will be suitable for advancing to clinical trials, this proposal is aligned with the National Vision Research Agenda's Needs, Gaps, and Opportunities for the NEI's Retinal Diseases Program strategic plan, and embraces the NIH Director's recent challenge to advance translational science using creative approaches.
Filed on September 01, 2016.
Tell us what you know about Jayakrishna Ambati's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Jayakrishna Ambati filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Jayakrishna Ambati | University of Kentucky | Conflict of Interest | Allergan | $60,000 - $79,999 |
| Jayakrishna Ambati | University of Kentucky | Conflict of Interest | iVeena Pharma, LLC | Value cannot be readily determined |
| Jayakrishna Ambati | University of Kentucky | Conflict of Interest | Inflammasome Therapeutics, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.